Pfizer's LITFULO Shows Strong Repigmentation in Vitiligo Trials, FDA Submission Planned
PFE sits 17% above its 52-week low of $23.62 on light trading volume (0.2× avg).
Summary
Pfizer presented detailed Phase 3 data for LITFULO in nonsegmental vitiligo at the EADV Congress. The 100mg dose achieved F-VASI75 in 21.86% of patients vs 2.40% on placebo, and T-VASI50 in 13.02% vs 2.40%. Safety was consistent with the known profile, with no new signals. The company plans to submit to FDA and EMA. This follows the July 30 topline announcement and adds the full efficacy and safety dataset, strengthening the case for a new oral systemic therapy in a disease with limited options. Regulatory submission timing will be a key next step.
At the time of this announcement, PFE was trading at $27.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $158B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.